Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-30

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether simvastatin is effective in the prevention of progression of porta hypertension in compensated cirrhosis patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Simvastatin in the Treatment of Portal Hypertension

NCT00594191

Cirrhosis Portal Hypertension

COMPLETED PHASE2

Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis

NCT03654053

Cirrhosis

ACTIVE_NOT_RECRUITING PHASE3

Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding

NCT01095185

Cirrhosis Hypertension, Portal Bleeding Esophageal Varices +1 more

COMPLETED PHASE3

Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis

NCT02643212

Cirrhosis

UNKNOWN PHASE3

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

NCT05516498

Liver Cirrhosis

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Decompensation of cirrhosis is associated with a dramatic reduction of survival. Progression of portal hypertension (PHT) is the main determinant of decompensation that appears when portal pressure gradient (PPG) is ≥10mmHg (clinically significant HTP). 40% of compensated cirrhotic patients have mild PHT. However, with progression of disease 41% develop clinically significant PHT. In cirrhosis, PHT results from increased resistance to blood flow, with a dynamic component due to decreased nitric oxide (NO) bioavailability. In advanced disease increased portal venous inflow also contributes to PHT. Beta-blockers have not been useful in compensated cirrhosis with mild PHT. In early cirrhosis, vasodilators may be more adequate. Statins, drugs that inhibit the activity of HMG-CoA reductase, induce selective hepatic vasodilation due to an enhanced bioavailability of NO. Acutely, they decreases hepatic resistance, while with long-term use statins decreases PPG without deleterious effects on systemic circulation. This multicenter, randomized, double-blind placebo-controlled study is aimed at assessing whether treatment with simvastatin may prevent progression of mild PHT (with PPG between 6 and 10 mmHg) to clinically significant PHT. Patients with compensated cirrhosis, without previous decompensation, without esophageal varices at risk and with PPG between 6 and 10 mmHg will be included. The calculated sample size is 80 patients and the duration of the study 4 years (2 years including and a follow-up of at least 2 year).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Portal Hypertension. Liver Cirrhosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

simvastatin

The experimental group will take simvastatin 40mg for at least two years.

Group Type EXPERIMENTAL

Simvastatin

Intervention Type DRUG

The experimental group will take 40 mg each 24 hours for at least two years.

placebo

the control group wiil take placebo pills for at least two years.

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

the control group wiil take placebo pills for at least two years.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Simvastatin

The experimental group will take 40 mg each 24 hours for at least two years.

Intervention Type DRUG

placebo

the control group wiil take placebo pills for at least two years.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Liver cirrhosis diagnosed by previous biopsy or by clinical, laboratory, ultrasound
* Portal hypertension gradient between6 mmHg and10 mmHg
* Absence of esophageal and gastric varices or small esophageal varices without red signs
* Absence previous episodes of gastrointestinal hemorrhage, ascites, encephalopathy or jaundice
* Written informed consent

Exclusion Criteria

* Age \<18 and\> 80 years,
* Presence or history of ascites, clinical or ultrasound,
* Previous decompensation of liver cirrhosis, ascites or SBP, bleeding varices, large varices, hepatic encephalopathy, jaundice,
* Thrombosis splenoportal,
* Hepatocellular carcinoma;
* Child-Pugh \>7 point
* Any comorbidity that leads to a restriction therapy and / or a life expectancy \<12 months
* Absolute contraindication to treatment with statins or allergy Simvastatin;
* Concomitant potent CYP3A4 inhibitors (eg., itraconazole, ketoconazole, protease inhibitors, HIV, erythromycin, clarithromycin, telithromycin and nefazodone),
* Pretreatment (\<1 month) with simvastatin or other lipid-lowering,
* Previous episodes of rhabdomyolysis,
* Active alcoholic hepatitis,
* Refusal to participate in the study or the informed consent claim;
* Pre-treatment with beta blockers or nitrates, or endoscopic treatment for varicose veins or portosystemic derivations;
* Pregnancy and lactation.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No